Sandra Van Schaeybroeck

7.1k total citations · 1 hit paper
60 papers, 5.5k citations indexed

About

Sandra Van Schaeybroeck is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sandra Van Schaeybroeck has authored 60 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 28 papers in Oncology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sandra Van Schaeybroeck's work include Colorectal Cancer Treatments and Studies (14 papers), Lung Cancer Treatments and Mutations (10 papers) and Ubiquitin and proteasome pathways (8 papers). Sandra Van Schaeybroeck is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Lung Cancer Treatments and Mutations (10 papers) and Ubiquitin and proteasome pathways (8 papers). Sandra Van Schaeybroeck collaborates with scholars based in United Kingdom, Ireland and United States. Sandra Van Schaeybroeck's co-authors include Patrick G. Johnston, Daniel B. Longley, Caitriona Holohan, Wendy L. Allen, Manuel Salto‐Tellez, Mark Lawler, Philip D. Dunne, Richard Turkington, Joan Kyula and Conor A. Bradley and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Sandra Van Schaeybroeck

59 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer drug resistance: an evolving paradigm

2013 3.6k citations Caitriona Holohan, Sandra Van Schaeybroeck et al. Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandra Van Schaeybroeck United Kingdom	24	3.3k	2.1k	1.1k	679	665	60	5.5k
Dong‐Hua Yang United States	41	3.2k 1.0×	2.1k 1.0×	813 0.7×	542 0.8×	459 0.7×	184	5.8k
Udai Banerji United Kingdom	40	4.3k 1.3×	2.7k 1.3×	1.2k 1.1×	1.2k 1.7×	506 0.8×	207	7.4k
Caitriona Holohan United Kingdom	13	2.6k 0.8×	1.3k 0.6×	823 0.7×	404 0.6×	602 0.9×	18	4.1k
Gavin P. Robertson United States	48	4.7k 1.4×	2.0k 1.0×	1.2k 1.1×	378 0.6×	538 0.8×	128	7.2k
Anna Dubrovska Germany	37	2.8k 0.9×	2.4k 1.1×	1.4k 1.3×	839 1.2×	411 0.6×	94	5.0k
Haiyong Han United States	44	4.8k 1.5×	2.1k 1.0×	1.1k 1.0×	366 0.5×	396 0.6×	114	7.1k
Judith Michels France	21	2.5k 0.8×	2.0k 1.0×	966 0.9×	563 0.8×	189 0.3×	55	4.7k
Carlo Leonetti Italy	41	3.2k 1.0×	1.8k 0.9×	684 0.6×	353 0.5×	247 0.4×	129	5.1k
Hermann Lage Germany	45	4.2k 1.3×	3.1k 1.5×	955 0.9×	346 0.5×	213 0.3×	173	6.7k
Niramol Savaraj United States	47	3.2k 1.0×	2.4k 1.1×	1.7k 1.6×	741 1.1×	335 0.5×	211	6.9k

Countries citing papers authored by Sandra Van Schaeybroeck

Since Specialization

Citations

This map shows the geographic impact of Sandra Van Schaeybroeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Van Schaeybroeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Van Schaeybroeck more than expected).

Fields of papers citing papers by Sandra Van Schaeybroeck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Van Schaeybroeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Van Schaeybroeck. The network helps show where Sandra Van Schaeybroeck may publish in the future.

Co-authorship network of co-authors of Sandra Van Schaeybroeck

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Van Schaeybroeck. A scholar is included among the top collaborators of Sandra Van Schaeybroeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Van Schaeybroeck. Sandra Van Schaeybroeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sessler, Tamas, Deborah Lavin, Vijay Tiwari, et al.. (2024). Ruthenium Drug BOLD-100 Regulates BRAF MT Colorectal Cancer Cell Apoptosis through AhR/ROS/ATR Signaling Axis Modulation. Molecular Cancer Research. 22(12). 1088–1101. 3 indexed citations

Burden, Roberta E., Ileana Micu, Richard D. Williams, et al.. (2022). USP17 is required for peripheral trafficking of lysosomes. EMBO Reports. 23(4). e51932–e51932. 11 indexed citations

Khawaja, Hajrah, Lyndsey Hanson, Alberto Bardelli, et al.. (2022). Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C -mutant Colorectal Cancer. Molecular Cancer Therapeutics. 22(1). 135–149. 8 indexed citations

Craig, Stephanie G., Victoria Bingham, Maurice B. Loughrey, et al.. (2021). Orthogonal MET analysis in a population‐representative stage II–III colon cancer cohort: prognostic and potential therapeutic implications. Molecular Oncology. 15(12). 3317–3328. 4 indexed citations

Khawaja, Hajrah, Andrew D. Campbell, Jamie Z. Roberts, et al.. (2020). RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. Cell Death and Disease. 11(10). 930–930. 14 indexed citations

Refaat, Alaa, Hajrah Khawaja, Wendy L. Allen, et al.. (2018). The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer. Molecular Cancer Therapeutics. 17(6). 1280–1290. 19 indexed citations

Smyth, Peter, Lai Jiang, Emma Evergren, et al.. (2018). USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells. Cell Communication and Signaling. 16(1). 77–77. 13 indexed citations

Dunne, Philip D., Darragh G. McArt, Paul G. O’Reilly, et al.. (2016). Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy. Cancer Immunology Research. 4(7). 582–591. 31 indexed citations

Dunne, Philip D., Darragh G. McArt, Conor A. Bradley, et al.. (2016). Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer. Clinical Cancer Research. 22(16). 4095–4104. 103 indexed citations

10.

Dunne, Philip D., Sonali Dasgupta, Jaine K. Blayney, et al.. (2015). EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. Clinical Cancer Research. 22(1). 230–242. 108 indexed citations

11.

Crawford, Nyree, Lucía Pérez–Carbonell, Mark Lawler, et al.. (2015). HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF -Mutant Colorectal Cancer by Downregulation of c-FLIPL. Clinical Cancer Research. 21(14). 3230–3240. 55 indexed citations

12.

Dunne, Philip D., Darragh G. McArt, Jaine K. Blayney, et al.. (2013). AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer. Clinical Cancer Research. 20(1). 164–175. 89 indexed citations

13.

Holohan, Caitriona, Sandra Van Schaeybroeck, Daniel B. Longley, & Patrick G. Johnston. (2013). Cancer drug resistance: an evolving paradigm. Nature reviews. Cancer. 13(10). 714–726. 3601 indexed citations breakdown →

14.

Allen, Wendy L., Richard Turkington, Leanne Stevenson, et al.. (2012). Pharmacogenomic Profiling and Pathway Analyses Identify MAPK-Dependent Migration as an Acute Response to SN38 in p53 Null and p53-Mutant Colorectal Cancer Cells. Molecular Cancer Therapeutics. 11(8). 1724–1734. 7 indexed citations

15.

Stevenson, Leanne, Wendy L. Allen, Richard Turkington, et al.. (2012). Identification of Galanin and Its Receptor GalR1 as Novel Determinants of Resistance to Chemotherapy and Potential Biomarkers in Colorectal Cancer. Clinical Cancer Research. 18(19). 5412–5426. 49 indexed citations

16.

Allen, Wendy L., Leanne Stevenson, Vicky M. Coyle, et al.. (2011). A Systems Biology Approach Identifies SART1 as a Novel Determinant of Both 5-Fluorouracil and SN38 Drug Resistance in Colorectal Cancer. Molecular Cancer Therapeutics. 11(1). 119–131. 30 indexed citations

17.

McLornan, Donal P., Helen L. Barrett, Robert Cummins, et al.. (2010). Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer. Clinical Cancer Research. 16(13). 3442–3451. 64 indexed citations

18.

Schaeybroeck, Sandra Van, Joan Kyula, Takehiko Sasazuki, et al.. (2010). Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM17. Cancer Research. 71(3). 1071–1080. 39 indexed citations

19.

Kyula, Joan, et al.. (2010). Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer. Clinical Cancer Research. 16(13). 3378–3389. 83 indexed citations

20.

Schaeybroeck, Sandra Van, Joan Kyula, Susan Stokesberry, et al.. (2008). Src and ADAM-17–Mediated Shedding of Transforming Growth Factor-α Is a Mechanism of Acute Resistance to TRAIL. Cancer Research. 68(20). 8312–8321. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact